China approves Sinopharm and Sinovac jabs for emergency use for children aged 3 to 17

About This Source - CGTN

This story is an English language news item from CGTN. CGTN is a Chinese state-funded broadcaster.

Recent from CGTN:

  • Life and reconstruction in Zhengzhou after heavy rain and flood
  • Figure skater Chen Lu winning an Olympic medal with Chinese flair
  • New Development Bank VP on post-pandemic recovery
  • CGTN published this video item, entitled “China approves Sinopharm and Sinovac jabs for emergency use for children aged 3 to 17” – below is their description.

    For more:

    https://news.cgtn.com/news/2021-06-12/China-approves-vaccines-for-emergency-use-for-children-aged-3-17-1123CSElSuc/index.html

    The #Sinopharm and #Sinovac #vaccines have been approved by Chinese health authorities for conditional marketing. Following their authorization for adults, they have continued to carry out expanded clinical trials, and they have been proven safe for the 3 to 17 age group after careful evaluation and expert reviews. The results show that these vaccines have a strong capability to induce the production of antibodies.

    CGTN YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    In This Story: Sinopharm

    China National Pharmaceutical Group Corp. known as Sinopharm is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group, China Traditional Chinese Medicine. Shanghai Shyndec Pharmaceutical and Beijing Tiantan Biological Products.

    2 Recent Items: Sinopharm

  • How a Senegal lab may be Africa’s pandemic game changer | COVID-19 Special
  • Live: Headline Buster – Why is the media stirring up controversy over Chinese vaccines?
  • Leave a Comment